Browse ANKH

Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Multi-pass membrane protein
Domain PF07260 Progressive ankylosis protein (ANKH)
Function

Regulates intra- and extracellular levels of inorganic pyrophosphate (PPi), probably functioning as PPi transporter.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001503 ossification
GO:0006817 phosphate ion transport
GO:0006820 anion transport
GO:0007626 locomotory behavior
GO:0015698 inorganic anion transport
GO:0030278 regulation of ossification
GO:0030282 bone mineralization
GO:0030500 regulation of bone mineralization
GO:0030505 inorganic diphosphate transport
GO:0031214 biomineral tissue development
GO:0035435 phosphate ion transmembrane transport
GO:0070167 regulation of biomineral tissue development
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
Molecular Function GO:0005315 inorganic phosphate transmembrane transporter activity
GO:0008509 anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015114 phosphate ion transmembrane transporter activity
GO:0015291 secondary active transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0030504 inorganic diphosphate transmembrane transporter activity
GO:1901677 phosphate transmembrane transporter activity
Cellular Component GO:0019867 outer membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-5223345: Miscellaneous transport and binding events
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANKH and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANKH in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANKH in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1910.0205
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.130.168
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5060.682
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1750.565
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3180.876
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0040.999
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1010.843
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1020.953
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1320.944
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2590.852
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7950.702
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4190.00801
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ANKH in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANKH. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANKH. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANKH.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANKH. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANKH expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANKH and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANKH
NameANKH inorganic pyrophosphate transport regulator
Aliases HANK; CPPDD; CCAL2; CMDJ; ankylosis, progressive (mouse) homolog; craniometaphyseal dysplasia, Jackson type ......
Chromosomal Location5p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANKH collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.